New Obesity Treatments on the Horizon: Biotech Stocks to Watch

"Eli Lilly Rises on Obesity Drug Demand, Eyes $1,033 Target"Подробнее

How GLP-1 Drugs Like Ozempic Are Boosting Biopharma StocksПодробнее

Altimmune CEO on what’s next for its experimental obesity drugПодробнее

Viking Therapeutics soars then drops on obesity dataПодробнее

Viking Therapeutics' shares soar on fresh weight-loss medication hopesПодробнее

Trade It or Fade It: The week's big biotech movesПодробнее

Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugsПодробнее

Biotech stock plays outside of GLP-1 weight-loss marketПодробнее

Stanley Druckenmiller’s $2.5 Billion Pivot: Bold Moves in 2024! Vertex Biotech Giant Make You Rich?Подробнее

Peptides for Progress: Limitless Biotech's Role in Obesity TreatmentПодробнее

New Global Guidelines: Redefining Obesity Diagnosis Beyond BMIПодробнее

Biotech stocks: Which drugmakers are worth a buy?Подробнее

Viking Joins Obesity Drug MarketПодробнее

Overlooked Stock: ISRGПодробнее

Viking's obesity drug study results are 'almost flawless', says Oppenheimer's Jay OlsonПодробнее

Investing in biotech outside of weight-loss drugsПодробнее

Amgen Stock Prediction: Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment.Подробнее

Top 10 Biotech Stocks you don't wanna miss in 2024.Подробнее